So far it is not clear how erythropoietin affects the anticoagulant properties of vascular endothelium in uremia. Since serotonin is also thought to play a role in the pathogenesis of thrombosis, the aim of the study was to evaluate major components of extrinsic coagulation pathway, markers of endothelial cell injury, lipoprotein (a) and peripheral serotonergic mechanisms during rHuEPO therapy in hemodialyzed patients. The study was performed on chronically hemodialyzed patients divided into two groups: with rHuEPO treatment and without rHuEPO therapy in relation to the control group. In uremic patients, thrombomodulin and von Willebrand factor, activity of factor VII, tissue factor pathway inhibitor (TFPI) activity, TFPI and tissue factor (TF) concentrations, lipoprotein (a) level were significantly higher when compared to healthy volunteers. Treatment with rHuEPO resulted in a further significant rise in markers of endothelial cell injury: thrombomodulin and von Willebrand factor and TFPI concentration. Extrinsic coagulation factors: activities of factor VII and X, TFPI activity and TF activity and concentration, lipoprotein (a) and vitronectin remained unchanged during rHuEPO therapy. Platelet serotonin content and whole blood serotonin were significantly lower in uremic patients relative to healthy volunteers and during rHuEPO treatment they increased significantly. Whole blood serotonin reached normal values. Plasma serotonin, significantly elevated in uremia, did not change during rHuEPO therapy. Serotonin uptake by uremic platelets was significantly impaired and remained unaltered during rHuEPO administration. Serotonin release by uremic platelets was also significantly depressed but a significant improvement was observed in rHuEPO-treated patients. Our data suggest that endothelial injury, TF pathway components and peripheral serotonergic system disturbances may predispose to thromboembolic complications and play a role in the pathogenesis of atherosclerosis in uremic patients, particularly treated with rHuEPO. Increase in TFPI may compensate the increase in TF in these patients.

1.
Eberst E, Berkowitz LR: Hemostasis in renal disease: Pathophysiology and management. Am J Med 1994;96:168–179.
2.
Locatelli F, Del Vecchio L, Manzoni C: Morbidity and mortality on maintenance hemodialysis. Nephron 1998;80:380–400.
3.
Bombeli T, Mueller M, Haeberli A: Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997;77:408–423.
4.
Wirtz JJM, van Esser JWJ, Hamulyak K, Leunissen KLM, van Hoof JP: The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients. Clin Nephrol 1992;38:277–282.
5.
Huraib S, Al-Momen AK, Gader AMA, Mitwalli A, Sulimani F, Abu-Aisha H: Effect of recombinant human erythropoietin on the hemostatic system in chronic hemodialysis patients. Clin Nephrol 1991;36:252–257.
6.
Takayama K: Changes in endothelial vasoactive substances and blood coagulation and fibrinolysis functions under recombinant human erythropoietin therapy in hemodialysis patients. Jpn J Nephrol 1993;35:197–188.
7.
Malyszko J, Malyszko JS, Borawski J, Rydzewski A, Kalinowski M, Azzadin A, Mysliwiec M, Buczko W: A study of platelet function, some hemostatic and fibrinolytic paramters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 1995;77:133–144.
8.
Van Zwieten PA: Pathophysiological relevance of serotonin. J Cardiovasc Pharmacol 1987;10(suppl 3):19–25.
9.
De Clerck F, van Nueten JM, Reneman RS: Platelet-vessel wall interactions: Implications of 5-hydroxytryptamine. A review. Agents Actions 1984;15:612–626.
10.
Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M: Coagulolytic system and endothelial function in cyclosporine-treated kidney alograft recipients. Transplantation 1996;62:828–830.
11.
Nakayama M, Yamada K, Yamamoto Y, Yokoyama K, Nakano H, Kubo H, Shigematsu T, Kawaguchi Y, Sakai O: Vascular dysfunction in patients on regular dialysis treatment. Clin Nephrol 1994;42:177–120.
12.
Malyszko J, Malyszko JS, Pawlak D, Pawlak K, Buczko W, Mysliwiec M: Platelet function, hemostasis and serotonin in acute and chronic renal failure. Thromb Res 1996;83:351.
13.
Willerson JT: Serotonin and thrombotic complications. J Cardiovasc Pharmacol 1991;17(suppl 5):513–520.
14.
Malyszko J, Urano T, Knofler R, Taminato A, Yoshimi T, Takada Y, Takada A: Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 1994;75:569–576.
15.
Picard M, Olichon D, Gombert J: Determination of serotonin in plasma by liquid chromatography with electrochemical detection. J Chromatogr 1985;341:445–451.
16.
Pawlak D, Malyszko J, Malyszko JS, Pawlak K, Buczko W, Mysliwiec M: Peripheral serotonergic system in uremia. Thromb Res 1996;83:189–194.
17.
Drummond A, Gordon J: Rapid sensitive microassay for platelet 5-HT. Thromb Diath Haemorrh (Stuttgart) 1974;31:366–367.
18.
Koutouzov S, Cothenet-Vernoux L, Marche P, Dausse JP: Influence of alpha- and beta-adrenoreceptors on thrombin-induced serotonin release in rat platelets. Thromb Res 1985;40:147–159.
19.
Gordon GL, Olverman HJ: 5-Hydroxytryptamine and dopamine transport by rat and human blood platelets. Br J Pharmacol 1978;62:219–226.
20.
Cella G, Vertolli U, Naso A, Vianello A, Rampin E, Sharai A, Boeri G, Strauss WE: Tissue factor pathway inhibitor activity in uremic patients during hemodialysis. Thromb Res 1996;81:671–677.
21.
Kario K, Matsuo T, Yamada T, Matsuo M: Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 1994;71:275–279.
22.
Kario K, Matsuo T, Matsuo M, Koide M, Yamada T, Nakamura S, Sakata T, Kato H, Miyata T: Marked increase of activated factor VII in uremic patients. Thromb Haemost 1995;73:763–767.
23.
Broze GJ Jr: Tissue factor pathway inhibitor. Thromb Haemost 1995;74:90–93.
24.
Koyama T, Nishida K, Ohdama S, Sawada M, Murakami N, Hirosawa S, Kuriyama R, Matsuzawa K, Hasegawa R, Aoki N: Determination of plasma tissue factor antigen and clinical significance. Br J Haematol 1994;87:343–347.
25.
Fukuda C, Iijima K, Nakamura K: Measuring tissue factor (factor III) activity in plasma. Clin Chem 1989;35:1897–1900.
26.
Sebekova K, Raucinova M, Dzurik R: Serotonin metabolism in patients with decreased renal function. Nephron 1989;53:229–232.
27.
Eknoyan G, Brown CH: Biochemical abnormalities of platelets in renal failure. Am J Nephrol 1981;1:17–21.
28.
Soslau G, Brodsky I, Putatunda B, Packer J, Schwartz AB: Selective reduction of serotonin storage and ATP release in chronic renal failure platelets. Am J Hematol 1990;35:171–176.
29.
Boucek RJ, Alvarez TR: 5-Hydroxytryptamine: A cytospecific growth stimulator of cultured fibroblasts. Science 1970;167:898–899.
30.
Aalto M, Kulonen M: Effects of serotonin, indomethacin and other antirheumatic drugs on the synthesis of collagen and other proteins in granulation tissue slices. Biochem Pharmacol 1972;21:2835–2840.
31.
Rossi P, Zamboni L: Pulmonary atherosclerosis due to serotonin. Nature 1958;181:1216–1217.
32.
Ahmed FS, Harrison CV: Morphological effects of serotonin on pulmonary arteries: An experimental study in rabbits. J Pathol Bacteriol 1964;87:3–5.
33.
Hunt BJ, Segal H, Yacoub M: Hemostatic changes in heart transplant recipients and their relationship to accelerated coronary sclerosis. Transplantation 1993;55:309–314.
34.
Preissner KT, Seiffert D: Role of vitronectin and its receptor in haemostasis and vascular remodeling. Thromb Res 1998;89:1–21.
35.
Cotran RS, Pober JS: Effects of cytokines on vascular endothelium: Their role in vascular and immune injury. Kidney Int 1989;35:969–975.
36.
Cotran RS, Pober JS: Cytokine-endothelial interaction in inflammation, immunity and vascular injury. J Am Soc Nephrol 1990;1:225–235.
37.
Bagdade JD: Chronic renal failure and atherogenesis. Serum factors stimulate the proliferation of human arterial smooth muscle cells. Atherosclerosis 1979;34:243–248.
38.
Strutz F, Muller GA: On the progression of chronic renal disease. Nephron 1995;69:371–379.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.